Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031770 | 0.84 | HRH1 (0.47) | HRH1HTR2A | |
| SCHEMBL6440586 | 0.75 | HRH1 (0.66) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| Fumaric Acid SCHEMBL7893815 | 0.75 | HRH1 (0.65) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| Fumaric Acid SCHEMBL6439646 | 0.75 | HRH1 (0.65) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| Hydrochloric Acid SCHEMBL6030979 | 0.73 | HRH1 (0.65) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| Vapitadine SCHEMBL6440903 | 0.68 | HRH1 (1.00) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| Vapitadine SCHEMBL29379463 | 0.68 | HRH1 (1.00) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| SCHEMBL6031358 | 0.67 | HRH1 (0.50) | HRH1HTR2AHTR2CHTR2BSIGMAR1 | |
| Vapitadine SCHEMBL3463472 | 0.67 | HRH1 (1.00) | HRH1HTR2AHTR2CDRD2SLC6A2 | |
| Fumaric Acid SCHEMBL6439581 | 0.67 | HRH1 (0.59) | HRH1HTR2AHTR2CDRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | claimed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | claimed |
| EP-1144411-B1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-04-27 | — | — | EP | claimed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | claimed |
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | disclosed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | HRH1 35/4885HTR2A 3106/4885HTR2C 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.